NCT02368743

Brief Summary

This national, observational and multicentre study aims at establishing a picture of real clinical practices management among patients treated with Pentasa®, according to the current therapeutic strategy in proctitis or distal proctosigmoiditis. This study should be able to provide data on patients' health related quality of life, compliance and efficacy in real clinical practice

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
117

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Dec 2015

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 16, 2015

Completed
7 days until next milestone

First Posted

Study publicly available on registry

February 23, 2015

Completed
9 months until next milestone

Study Start

First participant enrolled

December 1, 2015

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2017

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 2, 2018

Completed
Last Updated

July 5, 2018

Status Verified

July 1, 2018

Enrollment Period

1.2 years

First QC Date

February 16, 2015

Last Update Submit

July 3, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in Short Inflammatory Bowel Disease Questionnaire (SIBDQ) total score

    From baseline to week 8

Study Arms (1)

mesalazine

Treatment according to standard clinical practice.

Drug: mesalazine

Interventions

Also known as: Pentasa®
mesalazine

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Gastroenterologists with private and/or hospital practice

You may qualify if:

  • Patient aged 18 years or older.
  • Patient having received oral and written information on the study, without any objections for the use of his/her personal data, and having signed a written Informed Consent Form.

You may not qualify if:

  • Patient included in an interventional study assessing treatment for active proctitis or distal proctosigmoiditis.
  • Patient with left sided, colitis or pancolitis.
  • Patient previously treated with biologics.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Gastro-Entérologie et Hépatologie - CHU Brabois (there may be other sites in this country)

Vandœuvre-lès-Nancy, France

Location

Related Publications (1)

  • Paupard T, Gonzalez F, Caron B, Siproudhis L, Peyrin-Biroulet L. Real-world evidence of quality of life improvement in patients with distal ulcerative colitis treated by mesalazine: the Quartz study. Eur J Gastroenterol Hepatol. 2022 Dec 1;34(12):1203-1209. doi: 10.1097/MEG.0000000000002444. Epub 2022 Sep 12.

MeSH Terms

Interventions

Mesalamine

Intervention Hierarchy (Ancestors)

meta-AminobenzoatesAminobenzoatesBenzoatesAcids, CarbocyclicCarboxylic AcidsOrganic ChemicalsAminosalicylic AcidsSalicylatesHydroxybenzoatesHydroxy AcidsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsPhenols

Study Officials

  • Clinical Development Support

    Ferring Pharmaceuticals

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 16, 2015

First Posted

February 23, 2015

Study Start

December 1, 2015

Primary Completion

March 1, 2017

Study Completion

January 2, 2018

Last Updated

July 5, 2018

Record last verified: 2018-07

Locations